Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702

ID Number 14-2065-00002

Principal Investigator(s)
Keren Osman

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to learn how well maintenance treatment (chemotherapy) works to control your disease long-term (more than 3 years after transplant).  Multiple Myeloma (MM) is a cancer of the blood.  Because there's no cure for MM, maintenance treatment is given to slow the return of your disease after an autologous transplant.  An autologous transplant is one in which the stem cells are removed stored and given back to the same person.

We are doing this study to learn more about ways to prevent or delay relapse of multiple myeloma (MM).  We also want to know how well you do long-term (more than three years) after transplant.  You will get maintenance treatment and have a physical evaluation (test) every 6 months to see if you still have MM in your body.  This study will help doctors make the best choice about long-term treatment after autologous transplant for patients with MM.

Contact Information
Christine Woo
(212) 824-7309

Recruiting Patients: Yes